{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:26:46Z","timestamp":1788200806891,"version":"build-2803163510"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"73","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIACP101237-01"],"award-info":[{"award-number":["ZIACP101237-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As vaccination coverage expands, the epidemiology of human papillomavirus (HPV) infection and related disease is shifting. The declining prevalence of infections by the most high-risk HPV types, for example, HPV16 and HPV18, reduces the positive predictive value of screening tests for cervical precancer and cancer and challenges the balance between benefits and harms of current standard-of-care screening intervals. This evolving context raises an important policy question: Can and should cervical cancer screening eventually be reduced or even stopped in fully HPV-vaccinated populations?<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgag010","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:32:01Z","timestamp":1777289521000},"page":"173-179","source":"Crossref","is-referenced-by-count":1,"title":["Deintensification of cervical cancer screening in the era of high human papillomavirus\u2013vaccination coverage"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4853-6747","authenticated-orcid":false,"given":"Jesper","family":"Bonde","sequence":"first","affiliation":[{"name":"Department of Pathology, Copenhagen University Hospital, AHH-Hvidovre Hospital , Hvidovre,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip E","family":"Castle","sequence":"additional","affiliation":[{"name":"Divisions of Cancer Prevention and Cancer Epidemiology and Genetics, US National Cancer Institute, National Institutes of Health , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026083104014926900_lgag010-B1","author":"World Health Organization","year":"2024"},{"key":"2026083104014926900_lgag010-B2","author":"World Health Organization","year":"2020"},{"key":"2026083104014926900_lgag010-B3","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1093\/infdis\/jiae584","article-title":"Impact of multicohort human papillomavirus vaccination on cervical cancer in women below 30 years of age: lessons learned from the Scandinavian countries","volume":"231","author":"Nygard","year":"2025","journal-title":"J Infect Dis"},{"key":"2026083104014926900_lgag010-B4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/ijc.70286","article-title":"Challenges in the future of cancer screening","volume":"158","author":"Lynge","year":"2026","journal-title":"Int J Cancer"},{"key":"2026083104014926900_lgag010-B5","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/s41467-024-47909-x","article-title":"Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer","volume":"15","author":"Arroyo Muhr","year":"2024","journal-title":"Nat Commun"},{"key":"2026083104014926900_lgag010-B6","doi-asserted-by":"crossref","first-page":"101327","DOI":"10.1016\/j.lanepe.2025.101327","article-title":"The effect of bivalent HPV vaccination against invasive cervical cancer and cervical intraepithelial neoplasia grade 3 (CIN3+) in the Netherlands: a population-based linkage study","volume":"54","author":"Middeldorp","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026083104014926900_lgag010-B7","doi-asserted-by":"crossref","first-page":"101157","DOI":"10.1016\/j.lanepe.2024.101157","article-title":"Association between HPV vaccination and cervical screening policy changes and cervical cancer incidence and grade-3 cervical intraepithelial neoplasia incidence in England, 2006-2020: a population-based trends analysis","volume":"49","author":"Falcaro","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026083104014926900_lgag010-B8","doi-asserted-by":"crossref","first-page":"e077341","DOI":"10.1136\/bmj-2023-077341","article-title":"Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study","volume":"385","author":"Falcaro","year":"2024","journal-title":"BMJ"},{"key":"2026083104014926900_lgag010-B9","doi-asserted-by":"crossref","first-page":"2377903","DOI":"10.1080\/21645515.2024.2377903","article-title":"Long-term effectiveness of the nine-valent human papillomavirus vaccine: interim results after 12 years of follow-up in Scandinavian women","volume":"20","author":"Kjaer","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026083104014926900_lgag010-B10","doi-asserted-by":"crossref","first-page":"e1202","DOI":"10.1093\/infdis\/jiae209","article-title":"Quadrivalent HPV vaccine effectiveness against cervical intraepithelial lesion grade 2 or worse in Norway: a registry-based study of 0.9 million Norwegian women","volume":"230","author":"Orumaa","year":"2024","journal-title":"J Infect Dis"},{"key":"2026083104014926900_lgag010-B11","first-page":"CD015363","article-title":"Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination","volume":"11","author":"Henschke","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026083104014926900_lgag010-B12","first-page":"CD015364","article-title":"Human papillomavirus (HPV) vaccination for the prevention of cervical cancer and other HPV-related diseases: a network meta-analysis","volume":"11","author":"Bergman","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026083104014926900_lgag010-B13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"key":"2026083104014926900_lgag010-B14","doi-asserted-by":"crossref","first-page":"e2526683","DOI":"10.1001\/jamanetworkopen.2025.26683","article-title":"Cervical cancer screening, HPV vaccination, and cervical cancer elimination","volume":"8","author":"Luu","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026083104014926900_lgag010-B15","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/ijc.70297","article-title":"Predicting optimal impact interventions in the post-HPV vaccination world","volume":"158","author":"Lehtinen","year":"2026","journal-title":"Int J Cancer"},{"key":"2026083104014926900_lgag010-B16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/LGT.0000000000000573","article-title":"Human papillomavirus same genotype persistence and risk: a systematic review","volume":"25","author":"Bonde","year":"2021","journal-title":"J Low Genit Tract Dis"},{"key":"2026083104014926900_lgag010-B17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/LGT.0000000000000494","article-title":"Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review","volume":"24","author":"Bonde","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"2026083104014926900_lgag010-B18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"2026083104014926900_lgag010-B19","doi-asserted-by":"crossref","first-page":"101178","DOI":"10.1016\/j.lanepe.2024.101178","article-title":"Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study","volume":"49","author":"Wu","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026083104014926900_lgag010-B20","doi-asserted-by":"crossref","first-page":"200299","DOI":"10.1016\/j.tvr.2024.200299","article-title":"Analysis of the progression of cervical cancer in a low-and-middle-income country: from pre-malignancy to invasive disease","volume":"19","author":"Robinson","year":"2025","journal-title":"Tumour Virus Res"},{"key":"2026083104014926900_lgag010-B21","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1016\/j.vaccine.2023.10.002","article-title":"The impact of over ten years of HPV vaccination in England: surveillance of type-specific HPV in young sexually active females","volume":"41","author":"Checchi","year":"2023","journal-title":"Vaccine"},{"key":"2026083104014926900_lgag010-B22","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1016\/j.vaccine.2021.07.005","article-title":"Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction","volume":"39","author":"Shilling","year":"2021","journal-title":"Vaccine"},{"key":"2026083104014926900_lgag010-B23","doi-asserted-by":"crossref","first-page":"e2115321","DOI":"10.1001\/jamanetworkopen.2021.15321","article-title":"Modeling cervical cancer screening strategies with varying levels of human papillomavirus vaccination","volume":"4","author":"Grimes","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026083104014926900_lgag010-B24","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(21)02178-4","article-title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study","volume":"398","author":"Falcaro","year":"2021","journal-title":"Lancet"},{"key":"2026083104014926900_lgag010-B25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/ijc.33513","article-title":"Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: an ecological analysis on the effects of the school-based human papillomavirus vaccination program","volume":"149","author":"Donken","year":"2021","journal-title":"Int J Cancer"},{"key":"2026083104014926900_lgag010-B26","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2026083104014926900_lgag010-B27","doi-asserted-by":"crossref","first-page":"128142","DOI":"10.1016\/j.vaccine.2025.128142","article-title":"Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: the Trial23 cohort study","volume":"73","author":"Nonboe","year":"2026","journal-title":"Vaccine"},{"key":"2026083104014926900_lgag010-B28","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2025.30.27.2400820","article-title":"Human papillomavirus prevalence in first, second and third cervical cell samples from women HPV-vaccinated as girls, Denmark, 2017 to 2024: data from the Trial23 cohort study","volume":"30","author":"Nonboe","year":"2025","journal-title":"Euro Surveill"},{"key":"2026083104014926900_lgag010-B29","doi-asserted-by":"crossref","first-page":"e0306044","DOI":"10.1371\/journal.pone.0306044","article-title":"Screening outcome of HPV-vaccinated women: data from the Danish Trial23 cohort study","volume":"19","author":"Nonboe","year":"2024","journal-title":"PLoS One"},{"key":"2026083104014926900_lgag010-B30","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1080\/21645515.2018.1450125","article-title":"Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine","volume":"14","author":"Petry","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2026083104014926900_lgag010-B31","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/cncr.35334","article-title":"Top advances of the year: cervical cancer","volume":"130","author":"Duska","year":"2024","journal-title":"Cancer"},{"key":"2026083104014926900_lgag010-B32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1470-2045(22)00334-5","article-title":"Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis","volume":"23","author":"Athanasiou","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026083104014926900_lgag010-B33","doi-asserted-by":"crossref","first-page":"b2968","DOI":"10.1136\/bmj.b2968","article-title":"Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data","volume":"339","author":"Sasieni","year":"2009","journal-title":"BMJ."},{"key":"2026083104014926900_lgag010-B34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(10)70225-5","article-title":"Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data","volume":"11","author":"Donovan","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2026083104014926900_lgag010-B35","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1055-9965.EPI-20-1321","article-title":"The differential risk of cervical cancer in HPV-vaccinated and -unvaccinated women: a mathematical modeling study","volume":"30","author":"Naslazi","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026083104014926900_lgag010-B36","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.70229","article-title":"Controlled trial of cervical cancer screening frequency among human-papillomavirus-vaccinated women","volume":"158","author":"Ortega Llobet","year":"2026","journal-title":"Int J Cancer"},{"key":"2026083104014926900_lgag010-B37","doi-asserted-by":"crossref","first-page":"e075925","DOI":"10.1136\/bmj-2023-075925","article-title":"Untreated cervical intraepithelial neoplasia grade 2 and subsequent risk of cervical cancer: population based cohort study","volume":"383","author":"Lycke","year":"2023","journal-title":"BMJ"},{"key":"2026083104014926900_lgag010-B38","doi-asserted-by":"crossref","first-page":"k499","DOI":"10.1136\/bmj.k499","article-title":"Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis","volume":"360","author":"Tainio","year":"2018","journal-title":"BMJ"},{"key":"2026083104014926900_lgag010-B39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026083104014926900_lgag010-B40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.7326\/ANNALS-25-03192","article-title":"Optimizing cervical cancer screening by age of HPV vaccination: health and resource implications","volume":"179","author":"Pedersen","year":"2026","journal-title":"Ann Intern Med"},{"key":"2026083104014926900_lgag010-B41","year":"2026"},{"key":"2026083104014926900_lgag010-B42","author":"Health HTHCSoP","year":"2017"},{"key":"2026083104014926900_lgag010-B43","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"2026083104014926900_lgag010-B44","doi-asserted-by":"crossref","first-page":"356.e1","DOI":"10.1016\/j.ajog.2007.07.049","article-title":"Risk assessment to guide the prevention of cervical cancer","volume":"197","author":"Castle","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"2026083104014926900_lgag010-B45","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/aogs.14978","article-title":"Discontinuation of cervical cancer screening for HPV-vaccinated women?","volume":"103","author":"Bonde","year":"2024","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2026083104014926900_lgag010-B46","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/apm.12279","article-title":"Cervical cancer screening at crossroads","volume":"122","author":"Lynge","year":"2014","journal-title":"APMIS"},{"key":"2026083104014926900_lgag010-B47","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ypmed.2013.08.021","article-title":"Patient knowledge and beliefs as barriers to extending cervical cancer screening intervals in Federally Qualified Health Centers","volume":"57","author":"Hawkins","year":"2013","journal-title":"Prev Med"},{"key":"2026083104014926900_lgag010-B48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s43058-021-00211-z","article-title":"De-implementation and substitution of clinical care processes: stakeholder perspectives on the transition to primary human papillomavirus (HPV) testing for cervical cancer screening","volume":"2","author":"Hahn","year":"2021","journal-title":"Implement Sci Commun"},{"key":"2026083104014926900_lgag010-B49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/bmjqs-2025-018558","article-title":"Time to de-implementation of low-value cancer screening practices: a narrative review","volume":"34","author":"LeLaurin","year":"2025","journal-title":"BMJ Qual Saf"},{"key":"2026083104014926900_lgag010-B50","doi-asserted-by":"crossref","first-page":"e2011645","DOI":"10.1001\/jamanetworkopen.2020.11645","article-title":"Geographic variation in overscreening for colorectal, cervical, and breast cancer among older adults","volume":"3","author":"Moss","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026083104014926900_lgag010-B51","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0272989X221125168","article-title":"Rising to the de-escalation challenge: multilevel change needed to align clinical practice with cancer screening guidelines","volume":"42","author":"Schapira","year":"2022","journal-title":"Med Decis Making"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/173\/70870264\/lgag010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/173\/70870264\/lgag010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:01:57Z","timestamp":1788163317000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2026\/73\/173\/8776090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":51,"journal-issue":{"issue":"73","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgag010","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]}}}